Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 5.0 | 4.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 1.92 | 1.88 |
NAV | ₹440.82 | ₹40.63 |
Fund Started | 04 Jun 1999 | 25 Jun 2018 |
Fund Size | ₹3849.24 Cr | ₹5727.59 Cr |
Exit Load | Exit load of 0.50% if redeemed within 15 days | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 19.55% | 19.25% |
3 Year | 28.34% | 28.96% |
5 Year | 23.83% | 24.38% |
1 Year
3 Year
5 Year
Equity | 96.98% | 96.45% |
Cash | 2.94% | 3.55% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.19% |
Divi's Laboratories Ltd. | 7.78% |
Max Healthcare Institute Ltd. | 6.96% |
Lonza Group Ag | 4.76% |
Cipla Ltd. | 4.69% |
Lupin Ltd. | 4.23% |
Mankind Pharma Ltd. | 3.37% |
Abbott India Ltd. | 3.34% |
Fortis Healthcare Ltd. | 3.30% |
Aster DM Healthcare Ltd. | 3.25% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.23% |
Divi's Laboratories Ltd. | 8.95% |
Dr. Reddy's Laboratories Ltd. | 8.92% |
Cipla Ltd. | 7.75% |
Aurobindo Pharma Ltd. | 6.06% |
Biocon Ltd. | 5.02% |
Mankind Pharma Ltd. | 4.20% |
Alkem Laboratories Ltd. | 4.01% |
Lupin Ltd. | 3.79% |
Gland Pharma Ltd. | 3.57% |
Name | Tanmaya Desai | Dharmesh Kakkad |
Start Date | 27 Jun 2011 | 23 Feb 2021 |
Name
Start Date
Description | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 04 Jun 1999 | 25 Jun 2018 |
Description
Launch Date